Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest Therapeutics (Nasdaq: TPST) appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its Board effective June 4, 2026. They add experience in corporate finance and therapeutic product development, supporting Tempest’s CAR-T cell therapy portfolio and focus on growth and disciplined capital allocation.
Tempest Therapeutics (Nasdaq: TPST) entered a definitive agreement for the immediate cash exercise of warrants for 1,172,414 common shares at a reduced exercise price of $1.73 per share. This is expected to generate about $2 million in gross proceeds, plus up to $4 million from new short-term warrants if fully exercised.
The company will issue new unregistered short-term warrants for up to 2,344,828 shares at $1.73, expiring two years after issuance, and plans to use net proceeds for working capital and general corporate purposes.
Tempest Therapeutics (Nasdaq: TPST) reported Q1 2026 results and a business update. Interim data from TPST-2003 showed a 100% complete response rate in 15 CAR-T-naïve rrMM patients across REDEEM-1 and POEMS-1, with no Grade ≥3 CRS or ICANS in REDEEM-1.
AGCTC was named lead manufacturing partner and received the TPST-2003 lentiviral vector, supporting a planned U.S. registrational rrMM study in 2026. Tempest closed a strategic CAR-T asset acquisition from Factor Bioscience and Erigen, announced up to $6 million in private placement, ended Q1 with $1.8 million cash, and posted a $27.7 million net loss.
Tempest (NASDAQ: TPST) presented updated clinical data for dual-targeting CAR-T candidate TPST-2003 at ISCT on May 6, 2026. Key findings: a 100% complete response rate among 15 CAR-T‑naïve efficacy-evaluable patients across REDEEM-1 and POEMS-1, 44 patients treated to date, no dose-limiting toxicities, and no Grade >3 CRS or ICANS reported.
Data include 10/10 IMWG CR in REDEEM-1 rrMM patients, 5/5 CRVEGF in POEMS-1, and a reported median progression-free survival of 23.1 months noted as potentially class-leading if replicated in registrational trials.
Tempest (Nasdaq: TPST) will present clinical updates for its dual-targeting CAR-T candidate TPST-2003 at ISCT 2026 in Dublin, May 6-9. Data include REDEEM-1 Phase 1/2a interim results showing a 100% complete response rate among six then-evaluable patients per IMWG criteria and a reported favorable safety profile. Presentations include an oral talk (May 6) and poster reception (May 7).
Tempest (Nasdaq: TPST) delivered the TPST-2003 lentiviral vector to Cincinnati Children’s AGCTC, enabling manufacturing activities needed for pivotal development of the dual-targeting CD19/BCMA CAR-T for relapsed/refractory multiple myeloma.
Tempest reported a 100% overall response rate (25/25) across evaluable patients and 100% complete responses in six REDEEM-1 efficacy-evaluable patients; median PFS was 23.1 months in the investigator-initiated trial. Tech transfer is on track to support initiation of a potentially registrational study in Q4 2026.
Tempest (Nasdaq: TPST) appointed Andrew Fang, Ph.D., as Head of Business Development on April 14, 2026, to lead global partnerships, cross-border licensing and China outreach. The hire targets partnering for the Phase 3-ready small molecule amezalpat program and strategic collaborations across Tempest’s CAR-T portfolio.
The company noted prior regulatory alignment with FDA and EMA and clearance to pursue a pivotal trial of amezalpat in China, positioning the program for potential global development and regional licensing opportunities.
Tempest (Nasdaq: TPST) reported year-end 2025 results and a corporate update on March 30, 2026. Key developments include the strategic all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, positive interim REDEEM-1 data for TPST-2003 (100% CR in six evaluable patients), regulatory designations for amezalpat, and multiple equity financings.
Financially, cash fell to $7.7M at year-end 2025 from $30.3M, net loss was $26.3M, R&D spend was $12.6M, and Tempest noted partner-funded development strategies moving forward.
Tempest Therapeutics (Nasdaq: TPST) announced a private placement expected to close on or about March 23, 2026 to raise up to $6 million in aggregate proceeds: approximately $2 million upfront and up to $4 million if warrants are fully exercised.
The offering covers 925,927 shares (or pre-funded warrants) and accompanying series A and short-term series B warrants priced at $2.16 per share; warrants require stockholder approval and have defined expiry periods. Proceeds are for working capital and general corporate purposes.
Tempest (Nasdaq: TPST) selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) to conduct technology transfer, development and IND‑enabling manufacturing for TPST-2003, a dual‑targeting CD19/BCMA CAR‑T for relapsed/refractory multiple myeloma.
As of a January 31, 2026 cutoff, 36 patients received TPST-2003; all six efficacy‑evaluable REDEEM-1 patients achieved complete response and overall response rate was 100% (25/25) among evaluable patients. Most activities are planned complete by Q3 2026 to support a potential IND filing in Q4 2026.